Hookipa Biotech AG

Founded

2011

Staff

112

Organization type

RDM biotech/pharma

Region

Vienna

Cluster

LISAvienna

Focus

human health

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.

R&D:HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial. Our non-replicating prophylactic Cytomegalovirus candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation.